Published in J Virol on February 01, 2006
Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines (2012) 1.44
Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma. PLoS One (2009) 1.01
Adjuvantive effects of anti-4-1BB agonist Ab and 4-1BBL DNA for a HIV-1 Gag DNA vaccine: different effects on cellular and humoral immunity. Vaccine (2009) 0.99
Regulation of PI-3-Kinase and Akt Signaling in T Lymphocytes and Other Cells by TNFR Family Molecules. Front Immunol (2013) 0.99
Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine. Vaccine (2011) 0.98
Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business". J Virol (2007) 0.96
Macaque multimeric soluble CD40 ligand and GITR ligand constructs are immunostimulatory molecules in vitro. Clin Vaccine Immunol (2006) 0.95
Human glucocorticoid-induced TNF receptor ligand regulates its signaling activity through multiple oligomerization states. Proc Natl Acad Sci U S A (2008) 0.94
Tumor necrosis factor receptor/tumor necrosis factor family members in antiviral CD8 T-cell immunity. J Interferon Cytokine Res (2010) 0.92
Pharmacological modulation of GITRL/GITR system: therapeutic perspectives. Br J Pharmacol (2012) 0.91
CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. Cancer Immunol Immunother (2012) 0.86
beta-Glucan oligosaccharide enhances CD8(+) T cells immune response induced by a DNA vaccine encoding hepatitis B virus core antigen. J Biomed Biotechnol (2010) 0.85
Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands. BMC Immunol (2009) 0.84
DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers. J Virol (2015) 0.84
Principles of antibody-mediated TNF receptor activation. Cell Death Differ (2015) 0.84
Considerations for combined immune checkpoint modulation and radiation treatment. Radiat Res (2014) 0.81
Design of CD40 agonists and their use in growing B cells for cancer immunotherapy. Int Rev Immunol (2012) 0.81
Multifunctional CD40L: pro- and anti-neoplastic activity. Tumour Biol (2014) 0.81
Immunotargeting with CD154 (CD40 ligand) enhances DNA vaccine responses in ducks. Clin Vaccine Immunol (2006) 0.80
Binding Studies of TNF Receptor Superfamily (TNFRSF) Receptors on Intact Cells. J Biol Chem (2015) 0.80
Soluble CD40 ligand contributes to dendritic cell-mediated T-cell dysfunction in HIV-1 infection. AIDS (2015) 0.79
HIV-1 adenoviral vector vaccines expressing multi-trimeric BAFF and 4-1BBL enhance T cell mediated anti-viral immunity. PLoS One (2014) 0.79
Glucocorticoid-induced tumor necrosis factor receptor family-related protein triggering enhances HIV-specific CD4+ T cell cytokine secretion and protects HIV-specific CD4+ T cells from apoptosis. J Infect Dis (2007) 0.78
Enhancement of DNA Vaccine-induced Immune Responses by Influenza Virus NP Gene. Immune Netw (2009) 0.78
Modulation of HIV-1 immunity by adjuvants. Curr Opin HIV AIDS (2014) 0.78
EBV LMP1, a viral mimic of CD40, activates dendritic cells and functions as a molecular adjuvant when incorporated into an HIV vaccine. J Leukoc Biol (2011) 0.78
Latent Membrane Protein 1 as a molecular adjuvant for single-cycle lentiviral vaccines. Retrovirology (2011) 0.77
Design of vaccine adjuvants incorporating TNF superfamily ligands and TNF superfamily molecular mimics. Immunol Res (2013) 0.76
A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model. Vaccine (2015) 0.75
DNA/MVA Vaccines for HIV/AIDS. Vaccines (Basel) (2014) 0.75
Novel strategies to mimic transmembrane tumor necrosis factor-dependent activation of tumor necrosis factor receptor 2. Sci Rep (2017) 0.75
Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol (2004) 17.40
T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (1998) 12.70
The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell (2001) 12.59
A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature (1998) 12.07
Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature (1998) 11.08
HIV preferentially infects HIV-specific CD4+ T cells. Nature (2002) 9.28
The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell (1994) 9.25
Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol (2002) 9.18
CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity (2002) 8.28
Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity (2003) 5.52
Genetic immunization is a simple method for eliciting an immune response. Nature (1992) 5.30
The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell (1995) 5.08
Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8+ memory T cell subsets. Proc Natl Acad Sci U S A (2004) 4.93
Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem (2002) 4.60
DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol (2000) 4.51
The tumor necrosis factor ligand and receptor families. N Engl J Med (1996) 4.49
Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med (1998) 3.72
Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol (2004) 3.59
The molecular architecture of the TNF superfamily. Trends Biochem Sci (2002) 3.39
CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol (2004) 3.36
Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med (1999) 3.29
Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J Immunol (2004) 3.15
Functional impairment of CD8(+) T cells by regulatory T cells during persistent retroviral infection. Immunity (2004) 3.10
Collections and ficolins: humoral lectins of the innate immune defense. Annu Rev Immunol (2001) 2.90
Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med (2004) 2.89
A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol (2003) 2.85
Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol (1998) 2.82
CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med (1999) 2.61
Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci U S A (2004) 2.51
Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol (2003) 2.50
DNA vaccines: progress and challenges. J Immunol (2005) 2.34
Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. J Biol Chem (2003) 2.29
Regulatory CD4+CD25+ T cells restrict memory CD8+ T cell responses. J Exp Med (2002) 2.20
Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc Natl Acad Sci U S A (2003) 2.14
Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol (2001) 2.12
Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines. Proc Natl Acad Sci U S A (2004) 2.03
C1q and tumor necrosis factor superfamily: modularity and versatility. Trends Immunol (2004) 1.98
Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells. J Immunol (2004) 1.86
Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med (1997) 1.80
Cutting edge: the natural ligand for glucocorticoid-induced TNF receptor-related protein abrogates regulatory T cell suppression. J Immunol (2004) 1.79
Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine (2004) 1.74
Cloning of gp-340, a putative opsonin receptor for lung surfactant protein D. Proc Natl Acad Sci U S A (1999) 1.69
Short-circuiting long-lived humoral immunity by the heightened engagement of CD40. J Clin Invest (2002) 1.67
CD40-CD40 ligand interactions are critical in T-B cooperation but not for other anti-viral CD4+ T cell functions. J Exp Med (1996) 1.62
Memory B cells are biased towards terminal differentiation: a strategy that may prevent repertoire freezing. J Exp Med (1997) 1.59
Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J Virol (2003) 1.53
Molecular structure of pulmonary surfactant protein D (SP-D). J Biol Chem (1994) 1.51
Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science (2003) 1.48
Collectins: players of the innate immune system. Eur J Biochem (2004) 1.46
Prospects for an AIDS vaccine: three big questions, no easy answers. Lancet Infect Dis (2004) 1.46
Collectins--soluble proteins containing collagenous regions and lectin domains--and their roles in innate immunity. Protein Sci (1994) 1.45
Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. J Clin Invest (2004) 1.39
High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses. J Virol (2002) 1.37
Collectins and ficolins: sugar pattern recognition molecules of the mammalian innate immune system. Biochim Biophys Acta (2002) 1.36
Arrest of B lymphocyte terminal differentiation by CD40 signaling: mechanism for lack of antibody-secreting cells in germinal centers. Immunity (1998) 1.34
CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci U S A (2002) 1.34
Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154. Eur J Immunol (2001) 1.33
Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization. Int Immunol (1997) 1.33
CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. J Immunol (1998) 1.32
CD40 ligand (CD154) stimulation of macrophages to produce HIV-1-suppressive beta-chemokines. Proc Natl Acad Sci U S A (1998) 1.32
Developing DNA vaccines that call to dendritic cells. J Clin Invest (2004) 1.24
Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes. Hum Gene Ther (2002) 1.21
The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses. Immunol Rev (2004) 1.15
Modular organization of proteins containing C1q-like globular domain. Immunopharmacology (1999) 1.14
Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. J Virol (2001) 1.13
Incorporation of an isoleucine zipper motif enhances the biological activity of soluble CD40L (CD154). J Biol Chem (1999) 1.12
Microbial and T cell-derived stimuli regulate antigen presentation by dendritic cells in vivo. J Immunol (2000) 1.11
DNA vaccines for viral infections: basic studies and applications. Adv Virus Res (2000) 1.11
Systemic immunological effects of cytokine genes injected into skeletal muscle. Proc Natl Acad Sci U S A (1993) 1.10
Functional cooperation between T helper cell determinants. Proc Natl Acad Sci U S A (2000) 1.09
Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines. Curr Mol Med (2003) 1.06
DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev (2004) 1.06
Immunostimulatory effects of a plasmid expressing CD40 ligand (CD154) on gene immunization. J Immunol (1997) 1.04
Modulation of cellular responses by plasmid CD40L: CD40L plasmid vectors enhance antigen-specific helper T cell type 1 CD4+ T cell-mediated protective immunity against herpes simplex virus type 2 in vivo. Hum Gene Ther (2001) 0.99
A potent adjuvant effect of CD40 antibody attached to antigen. Immunology (2003) 0.98
CD40 cross-linking inhibits specific antibody production by human B cells. Int Immunol (1995) 0.98
Efficient priming of CD4+ and CD8+ T cells by DNA vaccination depends on appropriate targeting of sufficient levels of immunologically relevant antigen to appropriate processing pathways. J Immunol (2002) 0.96
Cutting edge: a potent adjuvant effect of ligand to receptor activator of NF-kappa B gene for inducing antigen-specific CD8+ T cell response by DNA and viral vector vaccination. J Immunol (2003) 0.96
The induction of HIV Gag-specific CD8+ T cells in the spleen and gut-associated lymphoid tissue by parenteral or mucosal immunization with recombinant Listeria monocytogenes HIV Gag. J Immunol (2003) 0.95
A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice. J Immunol (2001) 0.95
High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection. J Clin Invest (2001) 0.94
Immune responses to DNA vaccines. Cell Mol Life Sci (1999) 0.92
Kunjin virus replicon vectors for human immunodeficiency virus vaccine development. J Virol (2003) 0.91
Plasmids encoding granulocyte-macrophage colony-stimulating factor and CD154 enhance the immune response to genetic vaccines. Vaccine (2001) 0.89
CD80 and CD86, but not CD154, augment DNA vaccine-induced protection in experimental bovine tuberculosis. Vaccine (2004) 0.87
DNA vaccines against human immunodeficiency virus type 1. Immunol Rev (2004) 0.87
DNA immunisation: altering the cellular localisation of expressed protein and the immunisation route allows manipulation of the immune response. Vaccine (2004) 0.85
An expanding role for CD40L and other tumor necrosis factor superfamily ligands in HIV infection. J Hematother Stem Cell Res (2002) 0.85
CD40 ligand (CD154) improves the durability of respiratory syncytial virus DNA vaccination in BALB/c mice. Vaccine (2003) 0.84
Enhancement of antibody responses by DNA immunization using expression vectors mediating efficient antigen secretion. J Immunol Methods (1999) 0.83
Immunomodulatory effect of plasmids co-expressing cytokines in classical swine fever virus subunit gp55/E2-DNA vaccination. Vet Res (2005) 0.83
Interaction of B cells with activated T cells reduces the threshold for CD40-mediated B cell activation. Int Immunol (1999) 0.81
Immunomodulatory effect of a plasmid expressing CD40 ligand on DNA vaccination against human immunodeficiency virus type-1. Immunology (1999) 0.81
Biophysical characterization of a soluble CD40 ligand (CD154) coiled-coil trimer: evidence of a reversible acid-denatured molten globule. Arch Biochem Biophys (2001) 0.80
B-cell activation mediated by interactions with membranes from helper T cells. Adv Exp Med Biol (1992) 0.78
Computational design of variant TNF molecules: a novel methodology for inhibition of proinflammatory cascades. Sci STKE (2003) 0.76
Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science (2003) 10.79
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med (2002) 10.03
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis (2005) 3.93
Highly precise measurement of HIV DNA by droplet digital PCR. PLoS One (2013) 3.53
Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev (2004) 3.39
Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol (2004) 3.20
Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J Virol (2007) 2.47
Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc Natl Acad Sci U S A (2005) 2.42
Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J Virol (2004) 2.34
Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J Virol (2004) 2.27
T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction. Nature (2011) 2.26
Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. Int J Epidemiol (2004) 2.19
Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J Virol (2006) 2.16
Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis (2008) 2.08
Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J Virol (2005) 2.04
7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G. J Virol (2007) 1.91
Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology (2006) 1.86
Guidelines for naming nonprimate APOBEC3 genes and proteins. J Virol (2008) 1.86
Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J Mol Biol (2008) 1.83
DDB1 and Cul4A are required for human immunodeficiency virus type 1 Vpr-induced G2 arrest. J Virol (2007) 1.77
First snapshots of the HIV-1 RNA structure in infected cells and in virions. J Biol Chem (2004) 1.76
APOBEC3B deletion and risk of HIV-1 acquisition. J Infect Dis (2009) 1.74
Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J (2006) 1.64
Differential effects of p-glycoprotein and multidrug resistance protein-1 on productive human immunodeficiency virus infection. J Infect Dis (2002) 1.62
Herpes viruses and HIV-1 drug resistance mutations influence the virologic and immunologic milieu of the male genital tract. AIDS (2013) 1.60
Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. J Virol (2008) 1.57
Associations between virologic and immunologic dynamics in blood and in the male genital tract. J Virol (2011) 1.55
Differential inhibition of long interspersed element 1 by APOBEC3 does not correlate with high-molecular-mass-complex formation or P-body association. J Virol (2007) 1.53
Coinfection with HIV and hepatitis C virus among injection drug users in southern China. Clin Infect Dis (2005) 1.52
Structural insight into dGTP-dependent activation of tetrameric SAMHD1 deoxynucleoside triphosphate triphosphohydrolase. Nat Commun (2013) 1.50
Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection. J Virol (2003) 1.49
Dynamics of T cell responses in HIV infection. J Immunol (2002) 1.44
Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1. FASEB J (2008) 1.39
A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity. J Virol (2009) 1.38
Microarray analysis of microRNA expression in hepatocellular carcinoma and non-tumorous tissues without viral hepatitis. J Gastroenterol Hepatol (2008) 1.38
A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. J Virol (2009) 1.36
Molecular epidemiology of HIV-1 subtypes in southern China. J Acquir Immune Defic Syndr (2005) 1.33
Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligase. Proc Natl Acad Sci U S A (2009) 1.29
Characterization of a novel Cullin5 binding domain in HIV-1 Vif. J Mol Biol (2007) 1.27
Characterization of a thymus-tropic HIV-1 isolate from a rapid progressor: role of the envelope. Virology (2004) 1.26
STAT1-independent cell type-specific regulation of antiviral APOBEC3G by IFN-alpha. J Immunol (2006) 1.25
Characterization of full-length enterovirus 71 strains from severe and mild disease patients in northeastern China. PLoS One (2012) 1.24
Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins. PLoS One (2008) 1.23
Interaction with 7SL RNA but not with HIV-1 genomic RNA or P bodies is required for APOBEC3F virion packaging. J Mol Biol (2007) 1.23
Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system. J Virol (2003) 1.23
Association of human APOBEC3 cytidine deaminases with the generation of hepatitis virus B x antigen mutants and hepatocellular carcinoma. Hepatology (2007) 1.18
Modulation of LINE-1 and Alu/SVA retrotransposition by Aicardi-Goutières syndrome-related SAMHD1. Cell Rep (2013) 1.18
High prevalence and genetic diversity of HCV among HIV-1 infected people from various high-risk groups in China. PLoS One (2010) 1.15
Circulating coxsackievirus A16 identified as recombinant type A human enterovirus, China. Emerg Infect Dis (2011) 1.15
A novel DCAF1-binding motif required for Vpx-mediated degradation of nuclear SAMHD1 and Vpr-induced G2 arrest. Cell Microbiol (2012) 1.13
Interferon gene expression following HIV type 1 infection of monocyte-derived macrophages. AIDS Res Hum Retroviruses (2004) 1.13
Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype. Antimicrob Agents Chemother (2006) 1.13
Characterization of the interaction of full-length HIV-1 Vif protein with its key regulator CBFβ and CRL5 E3 ubiquitin ligase components. PLoS One (2012) 1.12
Gut Lactobacillales are associated with higher CD4 and less microbial translocation during HIV infection. AIDS (2013) 1.10
Adenovirus E4orf6 assembles with Cullin5-ElonginB-ElonginC E3 ubiquitin ligase through an HIV/SIV Vif-like BC-box to regulate p53. FASEB J (2007) 1.06
Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity. Leuk Res (2005) 1.05
Cytidine deaminase APOBEC3B interacts with heterogeneous nuclear ribonucleoprotein K and suppresses hepatitis B virus expression. Cell Microbiol (2007) 1.04
Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin. PLoS One (2012) 1.02
Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells. J Virol (2005) 1.01
Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma. PLoS One (2009) 1.01
In vitro suppression of human immunodeficiency virus type 1 replication by measles virus. J Virol (2005) 1.00
Differential requirements for HIV-1 Vif-mediated APOBEC3G degradation and RUNX1-mediated transcription by core binding factor beta. J Virol (2012) 0.99
Selection in context: patterns of natural selection in the glycoprotein 120 region of human immunodeficiency virus 1 within infected individuals. Genetics (2004) 0.99
Virion packaging determinants and reverse transcription of SRP RNA in HIV-1 particles. Nucleic Acids Res (2007) 0.99
Distinct viral determinants for the packaging of human cytidine deaminases APOBEC3G and APOBEC3C. Virology (2008) 0.99
Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine. Vaccine (2011) 0.98
Conserved and non-conserved features of HIV-1 and SIVagm Vif mediated suppression of APOBEC3 cytidine deaminases. Cell Microbiol (2008) 0.97
Identification of critical regions in human SAMHD1 required for nuclear localization and Vpx-mediated degradation. PLoS One (2013) 0.96
Macaque multimeric soluble CD40 ligand and GITR ligand constructs are immunostimulatory molecules in vitro. Clin Vaccine Immunol (2006) 0.95
Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4(+) T cells. AIDS (2013) 0.94
Host restriction of HIV-1 by APOBEC3 and viral evasion through Vif. Curr Top Microbiol Immunol (2009) 0.93
Protection from lethal challenge in a neonatal mouse model by circulating recombinant form coxsackievirus A16 vaccine candidates. J Gen Virol (2014) 0.93
The Vif accessory protein alters the cell cycle of human immunodeficiency virus type 1 infected cells. Virology (2006) 0.92
Core binding factor beta plays a critical role by facilitating the assembly of the Vif-cullin 5 E3 ubiquitin ligase. J Virol (2014) 0.92
Reduced APOBEC3H variant anti-viral activities are associated with altered RNA binding activities. PLoS One (2012) 0.92
Measles virus inhibits human immunodeficiency virus type 1 reverse transcription and replication by blocking cell-cycle progression of CD4+ T lymphocytes. J Gen Virol (2008) 0.91
CD44 microbeads accelerate HIV-1 infection in T cells. Virology (2009) 0.90
Persistent HIV-1-specific cellular responses despite prolonged therapeutic viral suppression. AIDS (2002) 0.89
The effect of RANTES chemokine genetic variants on early HIV-1 plasma RNA among African American injection drug users. J Acquir Immune Defic Syndr (2005) 0.88
Factors influencing a low rate of hepatitis C viral RNA clearance in heroin users from Southern China. World J Gastroenterol (2008) 0.87
Association of potent human antiviral cytidine deaminases with 7SL RNA and viral RNP in HIV-1 virions. J Virol (2010) 0.87
A first-in-class NAE inhibitor, MLN4924, blocks lentiviral infection in myeloid cells by disrupting neddylation-dependent Vpx-mediated SAMHD1 degradation. J Virol (2013) 0.86
CpG oligonucleotides partially inhibit growth of Mycobacterium tuberculosis, but not Salmonella or Listeria, in human monocyte-derived macrophages. FEMS Immunol Med Microbiol (2005) 0.85
Dispersed and conserved hydrophobic residues of HIV-1 Vif are essential for CBFβ recruitment and A3G suppression. J Virol (2013) 0.85
The HIV-1 Vif protein mediates degradation of Vpr and reduces Vpr-induced cell cycle arrest. DNA Cell Biol (2008) 0.85
HIV-1 Vif promotes the G₁- to S-phase cell-cycle transition. Blood (2010) 0.84
Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands. BMC Immunol (2009) 0.84
Lentiviral Vif: viral hijacker of the ubiquitin-proteasome system. Int J Hematol (2006) 0.84
Stable expression of primary human immunodeficiency virus type 1 structural gene products by use of a noncytopathic sindbis virus vector. J Virol (2002) 0.84
E1B 55k-independent dissociation of the DNA ligase IV/XRCC4 complex by E4 34k during adenovirus infection. Virology (2008) 0.84